Clinical Research Directory

Inclusion Criteria: * Have a diagnosis of cancer with no previous chemotherapy treatments (aside from current treatment) * Be scheduled to receive treatment with a chemotherapeutic agent that is classified by the National Comprehensive Cancer Network (NCCN) as having a high emetogenic potential (\>90% incidence) or moderate emetogenic potential (30-90% incidence). * Must be scheduled for a minimum of 3 additional chemotherapy cycles at the time of enrollment. * Chemotherapy agents may be given intravenously or orally. * Chemotherapy cycles must be at least two weeks apart. * For the purposes of this study, Day 1 is defined as the day of chemotherapy administration. * Chemotherapy may be for adjuvant, neoadjuvant, curative, or palliative intent. * Highly emetogenic - common types of chemotherapy * AC combination defined as any chemotherapy regimen that contains an anthracycline and cyclophosphamide * Carboplatin AUC ≥4 * Carmustine \>250 mg/m2 * Cisplatin * Cyclophosphamide \>1,500 mg/m2 * Dacarbazine * Doxorubicin ≥60 mg/m2 * Epirubicin \>90 mg/m2 * Ifosfamide ≥2 g/m2 per dose * Mechlorethamine * Streptozocin * Moderately emetogenic - common types of chemotherapy: * Aldesleukin \>12-15 million IU/m2 * Amifostine \>300 mg/m2 * Arsenic trioxide * Azacitidine * Bendamustine * Busulfan * Carboplatin AUC \<4 * Carmustined ≤250 mg/m2 * Clofarabine * Cyclophosphamide ≤1500 mg/m2 * Cytarabine \>200 mg/m2 * Dactinomycin * Daunorubicin * Dual-drug liposomal encapsulation of cytarabine and daunorubicin * Dinutuximab * Doxorubicind \<60 mg/m2 * Epirubicind ≤90 mg/m2 * Idarubicin * Ifosfamided \<2 g/m2 per dose * Interferon alfa ≥10 million IU/m2 * Irinotecan * Irinotecan (liposomal) * Melphalan * Methotrexated ≥250 mg/m2 * Oxaliplatin * Temozolomide * Trabectedin * Be willing to commit to the suggested medication dosing and delivery method, completing evaluation instruments, and attending all study visits. * Be able to understand English (all assessment instruments are in English). * Be 21 years of age or older. * Give informed consent. * Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, or abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. Exclusion Criteria: * Participants must not: * Use of any THC-containing cannabis products within 30 days prior to enrollment, verified by participant self-report. Allowable: Use of hemp-derived CBD products containing \< 0.3 % THC is permitted, consistent with the 2018 Agriculture Improvement Act (federal definition of hemp). Use of CBD products will be documented in baseline case report forms. * Have any allergies to cannabis or contraindication for cannabis. * Have an active or recent (\< 6 months) substance use disorder, as determined by medical history. * Have recently quit smoking (\< 6 months) or are actively engaged in a smoking-cessation program. * Have a history of severe anxiety or paranoia on prior exposure to cannabis. * Have a previous diagnosis of bipolar disorder or schizophrenia. * Be pregnant or nursing. * Have had a prior stroke. * Have moderate or severe chronic obstructive pulmonary disease (COPD), defined as FEV₁ \< 50 % predicted or current use of home supplemental oxygen.